Who
Heather Preston
Director
Company insider
Files Form 4 as: Director, Aligos Therapeutics; Director, Fusion Pharmaceuticals; Director, Akouos; Director, Karuna Therapeutics; Director, Alder Biopharmaceuticals; Director and 10% owner, Entasis Therapeutics Holdings; Director, Otonomy; Director, Albireo Pharma.
In numbers
- Trades disclosed
- 50
- Buys
- 9
- Sells
- 0
- Bought
- $10.7M
- Sold
- $0
- Companies
- 8
- Companies where not an officer
- 8
- First trade
- 19 May 2015
- Last trade
- 25 Jun 2026
- Last filed
- 29 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 25 Jun 2026filed 29 Jun 2026 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,860 at $0.00 | filing |
| 25 Jun 2026filed 29 Jun 2026 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,860 at $0.00 | filing |
| 25 Jun 2025filed 26 Jun 2025 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,860 at $0.00 | filing |
| 7 Aug 2024filed 9 Aug 2024 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —120,000 at $0.00 | filing |
| 14 Jun 2023filed 14 Jun 2023 | Fusion Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —17,000 at $0.00 | filing |
| 1 Dec 2022filed 2 Dec 2022 | Akouosoption or derivative | SEC FORM 4 Code D | —16,000 | filing |
| 30 Nov 2022filed 2 Dec 2022 | Akouos | SEC FORM 4 Code U | —5,882 | filing |
| 23 Jun 2022filed 27 Jun 2022 | Akouosoption or derivative | SEC FORM 4 Code A | —16,000 at $0.00 | filing |
| 14 Jun 2022filed 22 Jun 2022 | Fusion Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —17,000 at $0.00 | filing |
| 24 Jun 2021filed 28 Jun 2021 | Karuna Therapeutics | SEC FORM 4 Code J | —184 | filing |
| 24 Jun 2021filed 25 Jun 2021 | Akouosoption or derivative | SEC FORM 4 Code A | —16,000 at $0.00 | filing |
| 16 Jun 2021filed 23 Jun 2021 | Karuna Therapeuticsoption or derivative | SEC FORM 4 Code A | —8,500 at $0.00 | filing |
| 4 Jun 2021filed 7 Jun 2021 | Fusion Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —17,000 at $0.00 | filing |
| 8 Mar 2021filed 10 Mar 2021 | Karuna Therapeutics | SEC FORM 4 Code J | —572 | filing |
| 4 Sep 2020filed 9 Sep 2020 | Karuna Therapeutics | SEC FORM 4 Bought | $25K350 at $72.36 | filing |
| 30 Jun 2020filed 2 Jul 2020 | Fusion Pharmaceuticals | SEC FORM 4 Bought | $150K8,823 at $17.00 | filing |
| 30 Jun 2020filed 2 Jul 2020 | Akouosoption or derivative | SEC FORM 4 Code C | —1,499,971 at $0.00 | filing |
| 30 Jun 2020filed 2 Jul 2020 | Akouos | SEC FORM 4 Code C | —1,499,971 | filing |
| 30 Jun 2020filed 2 Jul 2020 | Akouos | SEC FORM 4 Bought | $5.0M294,117 at $17.00 | filing |
| 30 Jun 2020filed 2 Jul 2020 | Akouos | SEC FORM 4 Bought | $100K5,882 at $17.00 | filing |
News
No headline names them, or the companies they trade most, lately.